Ulimorelin
Overview[edit | edit source]
Ulimorelin is a ghrelin receptor agonist that has been investigated for its potential use in treating gastrointestinal motility disorders. It is a synthetic compound that mimics the action of the natural hormone ghrelin, which is known to stimulate appetite and increase gastrointestinal motility.
Chemical Structure[edit | edit source]
Ulimorelin is a small molecule with a specific chemical structure designed to bind to the ghrelin receptor. The structure of ulimorelin allows it to effectively mimic the action of ghrelin, thereby promoting gastrointestinal motility.
Mechanism of Action[edit | edit source]
Ulimorelin acts as an agonist at the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R1a). By activating this receptor, ulimorelin stimulates the release of growth hormone and enhances gastrointestinal motility. This action is particularly beneficial in conditions where gastrointestinal motility is impaired, such as gastroparesis.
Clinical Applications[edit | edit source]
Ulimorelin has been studied for its potential use in treating conditions like postoperative ileus and gastroparesis. These conditions are characterized by reduced gastrointestinal motility, leading to symptoms such as nausea, vomiting, and abdominal pain. By enhancing motility, ulimorelin may help alleviate these symptoms and improve patient outcomes.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of ulimorelin includes its absorption, distribution, metabolism, and excretion. Ulimorelin is typically administered intravenously, and its effects on gastrointestinal motility are observed shortly after administration. The metabolism of ulimorelin involves hepatic pathways, and it is excreted primarily through the kidneys.
Safety and Efficacy[edit | edit source]
Clinical trials have been conducted to evaluate the safety and efficacy of ulimorelin in various patient populations. These studies have shown that ulimorelin is generally well-tolerated, with a safety profile similar to other ghrelin receptor agonists. However, further research is needed to fully establish its efficacy in treating gastrointestinal motility disorders.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
